Form 8-K · Current Report · Filed 2025-05-01
DexCom Announces Q1 2025 Financial Results and $750M Share Repurchase Program
DexCom, Inc. reported its financial results for the quarter ended March 31, 2025, with revenue growing 12% year-over-year to $1.036 billion. The company also announced a share repurchase program of up to $750 million of its outstanding common stock. GAAP operating income was $133.7 million, while non-GAAP operating income was $143.1 million. DexCom updated its fiscal year 2025 guidance for Non-GAAP Gross Profit Margin and reiterated guidance for Revenue, Non-GAAP Operating Margin, and Adjusted EBITDA Margin.
- Filer
- Dexcom Inc. DXCM · NASDAQ
- Filed
- Accession
- 0001093557-25-000111
- CIK
- 0001093557
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$71.38
Next session
+14.3%
Since filing
+16.9%
Latest close
$83.45
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DXCM reporting the same item, with the next session's move:
Exhibits (1)
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Never miss another DXCM filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.